NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c and weight lowering than does escalating dulaglutide treatment. “Often, when we are with a patient who is not meeting treatment goals...
.png)
2488 Grand Concourse, suite 314, Bronx NY 10458
+1786-550-1661
info@holdingsolutioninc.com
Copyright © 2023 holdingsolutioninc. All Rights Reserved
